Figure S3 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. | Synapse
September 16, 2024
Figure S3 from De novo and histologically transformed small cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways.
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Figure S3: Lurbinectedin treatment induces regulators of the DNA damage response pathway.